NurExone Biologic

NRX.V

Biotechnology · Healthcare

Exchange

Toronto Stock Exchange Ventures

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

NurExone Biologic is a small biotechnology company focused on developing treatments for spinal cord injuries and other conditions that damage the nervous system. Its lead product, ExoPTEN, uses tiny biological particles called exosomes to deliver therapy directly to injured nerve tissue, with the goal of helping patients regain movement or sensation after serious injuries. The company is in the early clinical stage, meaning its treatments are still being tested and have not yet been approved for sale.

NurExone earns no significant revenue yet, as it is pre-commercial and relies on equity financing and grants to fund its research. The company is based in Israel and Canada, and its technology is built around a proprietary exosome platform, which it considers a key differentiator in the emerging field of exosome-based drug delivery. The main risk is typical for early-stage biotech: clinical trials may fail, regulatory approval is uncertain, and the company will need continued funding to advance its pipeline.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

Revenue data limited

EPS Growth

+16.6% YoY

YoY Growth Rate

Steady EPS growth

Insider Activity

24.3%ownership

Insiders own a meaningful stake in the company

Cash Runway

~4 months

C$2M cash & investments

Quarterly Free Cash Flow

→ Burn rate stable

Short runway — potential dilution ahead through share issuance

Cash watch

NurExone Biologic has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

—

Data not available

Profit after running costs

Operating Margin

N/A

—

Data not available

Return on the money invested

ROCE

-318.7%

Weak — -318.7% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

N/A

—

Data not available

Profit growth

EPS YoY

N/A

—

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial